Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors Journal Article
| Authors: | Palmerini, E.; Staals, E. L.; Maki, R. G.; Pengo, S.; Cioffi, A.; Gambarotti, M.; Picci, P.; Daolio, P. A.; Parafioriti, A.; Morris, C.; Antonescu, C. R.; Gronchi, A.; Casali, P. G.; Donati, D. M.; Ferrari, S.; Stacchiotti, S. |
| Article Title: | Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors |
| Abstract: | Background: Tenosynovial giant cell tumour/pigmented villonodular synovitis (TGCT/PVNS) is a benign neoplasm of synovium and tendon sheath. We conducted a retrospective pooled analysis in three major referral centers. Methods: Patients treated between 1998 and 2008 were examined. Only patients presenting with primary disease or first relapse were included. 5-year local failure free survival (5-yearLFFS) was analysed. Results: 294 patients were included: 254 with new diagnosis and 40 in 1st local recurrence (171 F/123 M; median age: 36 years; tumour size <= 2 cm in 27% of patients, >2 to <= 5 cm in 41%, and >5 cm in 32%). A diffuse pattern was reported in 69%, localised in 31%. No metastases were documented. Local failure (LF) was reported in 28% of patients: 36% in diffuse pattern, 14% in localised (p = 0.002); median time to LF: 16 months. With a median follow-up of 4.4 years, 5-year-LFFS was 66%, with multiple (up to five) local recurrences in 40% of relapsed patients. Size <2 cm, macroscopically complete resection, female gender and new diagnosis were associated with a better local control. After multivariate analysis, a previous relapse was independently associated with local failure. Conclusions: This study underlines the propensity of TGCT/PVNS to multiple local recurrences. In absence of clinical factors, biological studies are needed to identify prognostic factors of local failure. After a first local recurrence, surgery does not seem to have a curative potential. In these high risk patients, studies addressing the role of target therapies are needed. (C) 2014 Elsevier Ltd. All rights reserved. |
| Keywords: | treatment; imatinib; recurrence; tyrosine kinase inhibitors; prognostic factors; knee; tumor; expression; translocation; radiation-therapy; soft-tissue sarcomas; pigmented villonodular synovitis; diffuse; partial arthroscopic synovectomy; tenosynovial giant cell tumour |
| Journal Title: | European Journal of Cancer |
| Volume: | 51 |
| Issue: | 2 |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-01-01 |
| Start Page: | 210 |
| End Page: | 217 |
| Language: | English |
| ACCESSION: | WOS:000346851200010 |
| DOI: | 10.1016/j.ejca.2014.11.001 |
| PROVIDER: | wos |
| PUBMED: | 25465190 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work